JNJ-38877605 is an Orally Active c-Met Inhibitor for Solid Tumour Research
c-Met is a receptor tyrosine kinase involved in embryogenesis, wound healing, and tissue regeneration. Abnormal activation of the MET signaling pathway promotes the growth, survival, migration and invasion of tumor…